Insight into the FDA Approval of Biosimilar to Ustekinumab

In late October, the FDA approved the first biosimilar to ustekinumab to treat patients with psoriasis, psoriatic arthritis and other conditions. Ustekinumab-auub is expected to be available in the U.S. by 2025.

Source: The Rheumatologist - December 14, 2023 Category: Rheumatology Authors: Michele B. Kaufman, PharmD, BCGP Tags: Biologics/DMARDs Conditions Drug Updates Psoriatic Arthritis FDA approval U.S. Food and Drug Administration (FDA) ustekinumab Source Type: research